Cramer's 'Mad Money' Recap: Getting Good News From the Headlines
NEW YORK ( TheStreet) -- Just read the headlines and it's easy to see why the markets are back at five-year highs, according to Jim Cramer.
He told "Mad Money" viewers Monday that to find out why the markets keep rallying, they need only to read the front page of their newspapers.
Cramer said investors should, of course, always approach investing with at least a hint of worry. But today's markets are moving based on real economic demand, so much so the Federal Reserve may soon have to take notice and begin rolling back its stimulus.
So what are some of the things going right with our economy? Cramer pointed out a front-page story indicating the Republicans in the U.S. Congress may finally be willing to play ball with the Democrats and actually get some work done for a change. That's certainty positive.
Then there's a similar headline about a possible compromise on immigration reform. Wouldn't that be a boon for the U.S housing market if 11 million people could stop worrying about being thrown out of the country?
Other headlines continue to point to America's new oil and gas boom, which has not only put our country on the road to energy independence but also created tens of thousands of jobs in the process. Meanwhile, still other news stories point to a return of the retail investor to the markets -- more positive news.
At the individual company level, Cramer praised Hess (HES) for taking his advice and splitting itself up to bring out shareholder value. That stock soared 6% today. He said Transocean (RIG) announced similar plans.
All of these headlines add up to real reasons for being positive, said Cramer. Investors need to start taking notice.
In the "Executive Decision" segment, Cramer spoke with Dr. Phillip Frost, chairman and CEO of Opko Health (OPK) , a speculative biotech name that's rallied 55% since Cramer last spoke with Frost just three months ago.
Frost provided an update on the company's new vitamin D formulation for the treatment of renal disease. He said Opko's new formulation will address some four million patients, which represents a $12 billion market opportunity for the company because there are currently no adequate treatments for the disease. Additionally, Frost noted the market in Japan is almost as large.
When asked how Opko discovered the new formulation, Frost indicated it was one of many successful acquisitions his company has made over the years. He also cited Claros, an acquisition completed in October 2011, as another such highly lucrative deal. Okpo has also partnered with several larger drug makers and will share in the revenue on drugs developed through their combined efforts.